MXPA06004789A - Antagonistas del receptor de adenosina a2b. - Google Patents
Antagonistas del receptor de adenosina a2b.Info
- Publication number
- MXPA06004789A MXPA06004789A MXPA06004789A MXPA06004789A MXPA06004789A MX PA06004789 A MXPA06004789 A MX PA06004789A MX PA06004789 A MXPA06004789 A MX PA06004789A MX PA06004789 A MXPA06004789 A MX PA06004789A MX PA06004789 A MXPA06004789 A MX PA06004789A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- dione
- further characterized
- compound
- nitro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51601903P | 2003-10-31 | 2003-10-31 | |
| PCT/US2004/035453 WO2005042534A2 (en) | 2003-10-31 | 2004-10-26 | A2b adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06004789A true MXPA06004789A (es) | 2006-07-03 |
Family
ID=34549473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06004789A MXPA06004789A (es) | 2003-10-31 | 2004-10-26 | Antagonistas del receptor de adenosina a2b. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7449473B2 (enExample) |
| EP (1) | EP1678181B1 (enExample) |
| JP (1) | JP4863876B2 (enExample) |
| KR (1) | KR20060111467A (enExample) |
| CN (1) | CN1890241A (enExample) |
| AT (1) | ATE419252T1 (enExample) |
| AU (1) | AU2004285013A1 (enExample) |
| BR (1) | BRPI0415888A (enExample) |
| CA (1) | CA2544193C (enExample) |
| DE (1) | DE602004018808D1 (enExample) |
| ES (1) | ES2318363T3 (enExample) |
| MX (1) | MXPA06004789A (enExample) |
| WO (1) | WO2005042534A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| RS52455B (sr) * | 2004-09-01 | 2013-02-28 | Gilead Sciences Inc. | Postupak zarastanja rana primenom antagonista adenozinskog a2b receptora |
| US20060159627A1 (en) | 2004-10-15 | 2006-07-20 | Dewan Zeng | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| JP5044823B2 (ja) * | 2005-06-16 | 2012-10-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ａ２ｂアデノシンレセプターアンタゴニストのプロドラッグ |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| WO2007103776A2 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| EP2029603A1 (en) * | 2006-06-05 | 2009-03-04 | Astra Zeneca AB | Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| US7470697B2 (en) * | 2006-09-01 | 2008-12-30 | Adenosine Therapeutics, Llc | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors |
| GB0718432D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| GB0718434D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
| TW200938200A (en) * | 2007-12-28 | 2009-09-16 | Dainippon Sumitomo Pharma Co | Methyl-substituted piperidine derivative |
| JP5460690B2 (ja) | 2008-03-26 | 2014-04-02 | アドヴィナス・セラピューティックス・リミテッド | アデノシンレセプターアンタゴニストとしてのヘテロ環化合物 |
| EP2306838A4 (en) * | 2008-07-16 | 2011-12-14 | King Pharmaceuticals Res & Dev | METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| BRPI1009398A2 (pt) | 2009-03-13 | 2016-03-08 | Advinus Therapeutics Private Ltd | compostos de pirimidina fundida substituída |
| WO2011055391A1 (en) | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| US8815858B2 (en) * | 2010-05-21 | 2014-08-26 | Gilead Sciences, Inc. | Heterocyclic flaviviridae virus inhibitors |
| EP2616470B1 (en) | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| JP6132853B2 (ja) * | 2011-12-27 | 2017-05-24 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 全身性抗炎症反応を提供する、複数のプロスタグランジン受容体で作用する化合物 |
| WO2015003881A1 (en) * | 2013-07-08 | 2015-01-15 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| FI4122926T3 (fi) * | 2021-04-14 | 2025-07-23 | Shionogi & Co | Triatsiinijohdannaisia, joilla on viruksien replikaatiota estävää aktiivisuutta, ja niitä käsittävä lääkekoostumus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1254915B (it) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| DE19535504A1 (de) | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| US6117878A (en) | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| AU2001281802A1 (en) | 2000-06-07 | 2001-12-17 | Almirall Prodesfarma, S.A. | 6-phenylpyrrolopyrimidinedione derivatives |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| WO2003006465A1 (en) * | 2001-07-13 | 2003-01-23 | Cv Therapeutics, Inc. | Partial and full agonist of a adenosine receptors |
| PL370207A1 (en) | 2001-11-09 | 2005-05-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
-
2004
- 2004-10-26 MX MXPA06004789A patent/MXPA06004789A/es unknown
- 2004-10-26 DE DE602004018808T patent/DE602004018808D1/de not_active Expired - Lifetime
- 2004-10-26 AT AT04810023T patent/ATE419252T1/de not_active IP Right Cessation
- 2004-10-26 CN CNA200480031969XA patent/CN1890241A/zh active Pending
- 2004-10-26 AU AU2004285013A patent/AU2004285013A1/en not_active Abandoned
- 2004-10-26 BR BRPI0415888-1A patent/BRPI0415888A/pt not_active Application Discontinuation
- 2004-10-26 US US10/973,167 patent/US7449473B2/en not_active Expired - Lifetime
- 2004-10-26 ES ES04810023T patent/ES2318363T3/es not_active Expired - Lifetime
- 2004-10-26 WO PCT/US2004/035453 patent/WO2005042534A2/en not_active Ceased
- 2004-10-26 EP EP04810023A patent/EP1678181B1/en not_active Expired - Lifetime
- 2004-10-26 KR KR1020067008426A patent/KR20060111467A/ko not_active Withdrawn
- 2004-10-26 CA CA2544193A patent/CA2544193C/en not_active Expired - Lifetime
- 2004-10-26 JP JP2006538172A patent/JP4863876B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005042534A2 (en) | 2005-05-12 |
| US20050119287A1 (en) | 2005-06-02 |
| JP2007509947A (ja) | 2007-04-19 |
| CA2544193C (en) | 2012-03-27 |
| AU2004285013A1 (en) | 2005-05-12 |
| KR20060111467A (ko) | 2006-10-27 |
| US7449473B2 (en) | 2008-11-11 |
| ATE419252T1 (de) | 2009-01-15 |
| DE602004018808D1 (de) | 2009-02-12 |
| WO2005042534A3 (en) | 2005-08-25 |
| EP1678181A2 (en) | 2006-07-12 |
| EP1678181B1 (en) | 2008-12-31 |
| JP4863876B2 (ja) | 2012-01-25 |
| CN1890241A (zh) | 2007-01-03 |
| BRPI0415888A (pt) | 2007-01-09 |
| CA2544193A1 (en) | 2005-05-12 |
| ES2318363T3 (es) | 2009-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA06004789A (es) | Antagonistas del receptor de adenosina a2b. | |
| JP4350517B2 (ja) | Ａ２ｂアデノシン受容体アンタゴニスト | |
| US8324224B2 (en) | A2B adenosine receptor antagonists | |
| CN100415748C (zh) | A2b腺苷受体拮抗剂 | |
| US20030229106A1 (en) | A2B adenosine receptor antagonists | |
| AU2002359365A1 (en) | A2B adenosine receptor antagonists | |
| EP1622908B1 (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
| RU2318825C2 (ru) | Производные ксантина в качестве антагонистов a2b аденозинового рецептора | |
| HK1092137B (en) | Xanthine derivatives as a2b adenosine receptor antagonists | |
| KR20060055453A (ko) | Ａ2ｂ 아데노신 수용체 길항제로서의 크산틴 유도체 | |
| HK1071127B (en) | A2b adenosine receptor antagonists | |
| NZ573577A (en) | Xanthine derivatives as A2B adenosine receptor antagonists suitable for treating conditions such as asthma and diarrhoea |